€0.28
4.61% today
L&S, Jun 27, 03:39 pm CET
ISIN
IL0011313900
Symbol
GLMD
Sector
Industry

Galmed Pharmaceuticals Ltd. Share price

$0.31
-0.08 19.95% 1M
-0.12 27.88% 6M
-0.14 31.85% YTD
-3.03 90.72% 1Y
-46.94 99.34% 3Y
-96.59 99.68% 5Y
-146.69 99.79% 10Y
Nasdaq, Closing price Wed, Jun 26 2024
ISIN
IL0011313900
Symbol
GLMD
Sector
Industry

Key figures

Market capitalization $1.86m
Enterprise Value $-9.07m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.45
P/B ratio (TTM) P/B ratio 0.15
Turnover (TTM) Turnover $0.00
EBIT (operating result TTM) EBIT $-6.89m
Free cash flow (TTM) Free cash flow $-6.27m
Cash position $10.93m
EPS (TTM) EPS $-1.82
Short interest 0.41%
Show more

Is Galmed Pharmaceuticals Ltd. a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,947 shares worldwide.

Galmed Pharmaceuticals Ltd. Share analysis

Unlock scores for free

Analyst opinions

1 Analyst has issued a forecast Galmed Pharmaceuticals Ltd.:

1x Buy
100%

Analyst opinions

1 Analyst has issued a forecast Galmed Pharmaceuticals Ltd.:

Buy
100%

Financial data from Galmed Pharmaceuticals Ltd.

Profit and loss account P&L | Balance sheet | Cash flow


Quarter TTM Annually
Mar '24
+/-
%
- -
-
100%
- Direct costs 0.04 0.04
100% 100%
-
-0.04 -0.04
-
-
- Selling and administrative expenses 3.69 3.69
13% 13%
-
- Research and development costs 3.12 3.12
66% 66%
-
-6.85 -6.85
49% 49%
-
- Depreciation and amortization 0.04 0.04
-
-
EBIT (operating result) EBIT -6.89 -6.89
49% 49%
-
Net profit -6.36 -6.36
53% 53%
-

Figures in millions USD.

Don't miss a thing! We will send you all news about the Galmed Pharmaceuticals Ltd. share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Galmed Pharmaceuticals Ltd. Share News

Positive
InvestorPlace
3 months ago
Now could be a great time for investors to consider stacking up on penny stocks. These companies often have significant growth potential.
Neutral
PRNewsWire
3 months ago
TEL AVIV, Israel , April 4, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission (the "SEC").
Neutral
PRNewsWire
3 months ago
TEL AVIV, Israel , March 15, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases announced today the grant of a European patent related to the use of a combination of Aramchol and Resmetirom (MGL-3196, REZDIFFRA) for the treatment of NASH/MASH and liver fibrosis.
More Galmed Pharmaceuticals Ltd. News

Company profile

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

Head office Israel
CEO Allen Baharaff
Employees 8
Founded 2000
Website galmedpharma.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now